Quest Diagnostics stock falls as Medicare cuts threaten 2027 earnings

Quest Diagnostics (ISIN US74834L1008) closed at USD 246.48 on the NYSE on September 22, 2026, after a proposed Medicare reimbursement cut of up to 15 percent put pressure on the laboratory operator's 2027 earnings outlook. The stock had reached an intraday 52-week high of USD 248.84 on September 21, 2026, making the policy proposal a sharp counterweight to its recent market strength.

Medicare proposal changes the outlook

According to Investing.com on September 22, 2026, the proposed PAMA reductions are reflected in the low end of Quest Diagnostics' previously provided adjusted earnings-per-share growth target of 7 percent to 9 percent. The proposal could reduce laboratory fee payments by as much as 15 percent from January 1, 2027, which makes reimbursement policy the key downside variable for routine clinical testing.

Investing.com reported on September 22, 2026, that Evercore estimated a USD 90 million to USD 100 million impact on adjusted operating income in 2027. The firm said the effect could translate into a low-to-mid single-digit percentage impact on earnings per share and push results toward the lower half of the long-term guidance range.

Second-quarter results provide support

The latest reported quarter was Quest Diagnostics' second quarter of 2026. Revenue reached USD 3.04 billion, while adjusted earnings per share came to USD 3.12, beating the cited consensus estimate of USD 2.82 by USD 0.30, according to Ad-hoc-News on September 22, 2026. That quantified earnings beat contrasts with the reimbursement risk because the operational data remain supportive while the policy effect is prospective.

Analyst targets also moved higher after the second-quarter performance. According to Investing.com on September 22, 2026, Truist Securities raised its target from USD 225 to USD 250 while retaining a Hold rating, and UBS lifted its target from USD 232 to USD 245 while keeping a Neutral rating. The target increases show that stronger near-term execution has not removed the longer-term reimbursement debate.

Quest Diagnostics stock stays near high

Quest Diagnostics stock closed only USD 2.36 below the reported 52-week high of USD 248.84 on September 22, 2026. The same market snapshot placed market capitalization at USD 25.93 billion and year-to-date price performance at 43 percent, so the policy headline arrived after a substantial 2026 advance rather than after a prolonged decline.

The next scheduled operating checkpoint is already dated. According to KXAN on September 22, 2026, Quest Diagnostics will release third-quarter 2026 financial results before the market opens on October 22, 2026, followed by a conference call at 8:30 a.m. Eastern Time. That report should clarify how management frames demand, guidance and the proposed reimbursement changes.

Stock remains close to yearly high

At USD 246.48 on the NYSE as of September 22, 2026, Quest Diagnostics stock remained close to its USD 248.84 52-week high. Market capitalization stood at USD 25.93 billion on the same date, while the proposed 15 percent Medicare reduction and the USD 3.12 second-quarter adjusted EPS result define the competing forces for the next earnings update.

More news and analyses on Quest Diagnostics stock